Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy

In this review, Wei Jin and colleagues from the University of Missouri-Kansas City, Missouri, USA, have summarised the ligands associated with prostate-specific membrane antigen (PSMA), which is a widely used biomarker and antigen in prostate cancer diagnosis. This topic is one of the most attractive and promising subjects in the diagnosis and therapy of prostate cancer, and will be of great interest to our readers. Dr A. Erdem Canda

Wei Jin, Ashutosh Barve, *Kun Cheng

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri–Kansas City, Kansas City, Missouri, USA
*Correspondence to chengkun@umkc.edu

Disclosure: The authors have declared no conflicts of interest.
Received: 17.11.2015 Accepted: 06.01.2016
Citation: EMJ Urol. 2016;4[1]:62-69.


Prostate-specific membrane antigen (PSMA) is the most extensively studied biomarker and antigen of prostate cancer. It is overexpressed in almost all prostate cancers, and the expression level increases with prostate cancer progression. PSMA is also highly expressed in the neovasculature of solid tumours including prostate cancer. As a result, numerous PSMA-specific ligands have been discovered for prostate cancer diagnosis and therapy, and one of them has been approved for clinical use. Moreover, a number of other PSMA-specific ligands are currently evaluated in clinical studies. In this review we discuss four major types of PSMA-specific ligands, including antibody, aptamer, peptide, and small molecule inhibitor. Their emerging applications in prostate cancer diagnosis, targeted drug delivery, and therapy are also discussed.

Download (PDF, 340KB)

Comments are closed.